Eli Lilly seems to have responded to the threat by President Donald Trump of tariffs on the pharma industry if they don't relocate their manufacturing operations to the US. The pharma group has just ...
ImmunoGenAlmost four years after backing out of an antibody-drug conjugate (ADC) alliance with ImmunoGen, Eli Lilly has come back to the table with a new, wide-ranging deal worth up to $1.7 billion.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback